This week SNMMI and its coalition partners sent a letter imploring Congress to take immediate action to ensure patient access to FDA-approved diagnostic radiopharmaceutical drugs that aid in the detection of cancer, cardiovascular conditions and neurological disorders. Mounting evidence shows that COVID-19 infection damages not only the respiratory system, but also the heart and other organ systems. Furthermore, the long-term effects of this disease are still unknown. Patients who survive COVID-19 will need access to the best care available, and nuclear medicine is an essential part of that care.
To read more please visit: